Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) announced on September 30, 2026 that it has completed enrollment in its BASECAMP Phase 2 clinical trial evaluating forazapadin for Duchenne muscular dystrophy (DMD) in ambulatory boys aged 7 to 10. The company states it surpassed its enrollment target in less than nine months from screening its first participant. Topline clinical data are now expected in the first quarter of 2027, a revision to the company's previous data-release timeline. Investors in the clinical-stage drug developer may be watching the forthcoming dataset closely given the company's stated interest in exploring an accelerated regulatory development pathway.

Key Points

  • Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)
  • Enrollment in the BASECAMP Phase 2 trial of forazapadin in pediatric DMD patients is now complete, exceeding the original target
  • Topline data expected Q1 2027; trial spans 18 sites across seven countries with participants randomised to forazapadin 60 mg, 120 mg, or placebo
  • Investors may be watching whether BASECAMP data support discussions with the FDA regarding a potential accelerated development pathway for forazapadin

BASECAMP Trial Design and Global Reach

The BASECAMP study enrolled ambulatory boys aged 7 to 10 across 18 clinical sites in the United States, Canada, Australia, Belgium, Spain, Poland, and Serbia. Participants were randomised 1:1:1 to receive forazapadin 60 mg, forazapadin 120 mg, or placebo. The trial includes a 12-week placebo-controlled period followed by a 36-week randomised active-treatment period. Primary endpoints cover safety, tolerability, and the effect of forazapadin on muscle force as assessed by dynamometry, while secondary endpoints are designed to assess the drug's impact on muscle quality, function, and regeneration.

Forazapadin's Mechanism and DMD Development Rationale

Forazapadin is an orally administered small molecule drug candidate that targets AAK1, a protein Satellos has identified as believed to help restore the body's natural muscle repair and regeneration biology. The company states forazapadin is being developed as a potential DMD treatment independent of dystrophin and applicable regardless of exon mutation status, as either a stand-alone or adjunctive therapy. Satellos is also evaluating forazapadin in adults living with DMD through its TRAILHEAD open-label study, and a Phase 2 trial in facioscapulohumeral muscular dystrophy is expected to begin in the fourth quarter of 2026.

Data Timeline Revised to Allow Comprehensive Dataset

The company disclosed that it has adjusted its previous data-release plan in order to compile what it describes as the most complete dataset possible. The release states that management believes BASECAMP could support discussions with the FDA regarding a potential accelerated development pathway for forazapadin. Satellos indicated this consideration influenced the decision to revise the data-release timeline, with topline results now targeted for Q1 2027. The immediate share price impact was not clear from available public information.